BlackRock’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,663,678
| Closed | -$10.7M | – | 5521 |
|
|
2025
Q2 | $10.7M | Sell |
2,663,678
-1,081,439
| -29% | -$2.68M | ﹤0.01% | 3384 |
|
|
2025
Q1 | $3.41M | Sell |
3,745,117
-67,422
| -2% | -$93.5K | ﹤0.01% | 3795 |
|
|
2024
Q4 | $10.6M | Buy |
3,812,539
+321,303
| +9% | +$1.22M | ﹤0.01% | 3398 |
|
|
2024
Q3 | $18.3M | Buy |
3,491,236
+148,043
| +4% | +$768K | ﹤0.01% | 3097 |
|
|
2024
Q2 | $14.9M | Buy |
3,343,193
+254,540
| +8% | +$1.23M | ﹤0.01% | 3155 |
|
|
2024
Q1 | $23.7M | Buy |
3,088,653
+46,323
| +2% | +$254K | ﹤0.01% | 2892 |
|
|
2023
Q4 | $13M | Buy |
3,042,330
+802,588
| +36% | +$2.85M | ﹤0.01% | 3257 |
|
|
2023
Q3 | $9.41M | Buy |
2,239,742
+300,082
| +15% | +$1.53M | ﹤0.01% | 3368 |
|
|
2023
Q2 | $10.8M | Buy |
1,939,660
+1,488,467
| +330% | +$8.8M | ﹤0.01% | 3380 |
|
|
2023
Q1 | $2.59M | Buy |
451,193
+24,969
| +6% | +$66K | ﹤0.01% | 3933 |
|
|
2022
Q4 | $448K | Sell |
426,224
-2,207
| -0.5% | -$3.86K | ﹤0.01% | 4641 |
|
|
2022
Q3 | $1.15M | Sell |
428,431
-2,089
| -0.5% | -$7.56K | ﹤0.01% | 4432 |
|
|
2022
Q2 | $2.05M | Sell |
430,520
-447,880
| -51% | -$1.95M | ﹤0.01% | 4244 |
|
|
2022
Q1 | $3.59M | Buy |
878,400
+41,402
| +5% | +$244K | ﹤0.01% | 4127 |
|
|
2021
Q4 | $5.71M | Sell |
836,998
-63,721
| -7% | -$550K | ﹤0.01% | 3939 |
|
|
2021
Q3 | $10.4M | Buy |
900,719
+846
| +0.1% | +$13.2K | ﹤0.01% | 3653 |
|
|
2021
Q2 | $15.3M | Buy |
899,873
+38,190
| +4% | +$664K | ﹤0.01% | 3450 |
|
|
2021
Q1 | $17.1M | Buy |
861,683
+230,932
| +37% | +$5.1M | ﹤0.01% | 3266 |
|
|
2020
Q4 | $13M | Buy |
630,751
+129,817
| +26% | +$3.09M | ﹤0.01% | 3236 |
|
|
2020
Q3 | $13.2M | Buy |
+500,934
| New | +$12.4M | ﹤0.01% | 3083 |
|
BlackRock's INZY Position: Q3 2025 in Review
BlackRock sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 2,663,678 shares — an estimated $10.7M sold.
BlackRock first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $23.7M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- BlackRock reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 2,663,678 Inozyme Pharma shares in Q3 2025, an estimated $10.7M.
- BlackRock first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- BlackRock's Inozyme Pharma position peaked at $23.7M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.